Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.130
-0.160 (-3.73%)
At close: Aug 24, 2026, 4:00 PM EDT
4.174
+0.044 (1.07%)
After-hours: Aug 24, 2026, 7:30 PM EDT
Ironwood Pharmaceuticals Revenue
Ironwood Pharmaceuticals had revenue of $113.04M in the quarter ending June 30, 2026, with 32.62% growth. This brings the company's revenue in the last twelve months to $389.32M, up 26.19% year-over-year. In the year 2025, Ironwood Pharmaceuticals had annual revenue of $296.15M, down -15.72%.
Revenue (ttm)
$389.32M
Revenue Growth
+26.19%
P/S Ratio
1.78
Revenue / Employee
$3,893,160
Employees
100
Market Cap
682.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 296.15M | -55.26M | -15.72% |
| Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
| Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
| Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
| Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
| Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
| Dec 31, 2019 | 428.41M | 81.77M | 23.59% |
| Dec 31, 2018 | 346.64M | 48.36M | 16.21% |
| Dec 31, 2017 | 298.28M | 24.32M | 8.88% |
| Dec 31, 2016 | 273.96M | 124.40M | 83.18% |
| Dec 31, 2015 | 149.56M | 73.12M | 95.66% |
| Dec 31, 2014 | 76.44M | 53.56M | 234.06% |
| Dec 31, 2013 | 22.88M | -127.36M | -84.77% |
| Dec 31, 2012 | 150.25M | 84.37M | 128.09% |
| Dec 31, 2011 | 65.87M | 22.01M | 50.19% |
| Dec 31, 2010 | 43.86M | 9.54M | 27.78% |
| Dec 31, 2009 | 34.32M | 15.94M | 86.70% |
| Dec 31, 2008 | 18.38M | 7.92M | 75.68% |
| Dec 31, 2007 | 10.46M | 7.32M | 233.25% |
| Dec 31, 2006 | 3.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Evotec SE | 819.47M |
| Collegium Pharmaceutical | 808.21M |
| Pacira BioSciences | 746.16M |
| Amphastar Pharmaceuticals | 730.02M |
| Evolus | 316.49M |
| Canopy Growth | 206.77M |
| Kamada | 191.85M |
IRWD News
- 18 days ago - Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Ironwood Pharmaceuticals Earnings release: Q2 2026 - Filings
- 18 days ago - Ironwood Pharmaceuticals Slides: Q2 2026 - Filings
- 18 days ago - Ironwood Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 18 days ago - Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Business Wire
- 25 days ago - Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call - Business Wire
- 5 weeks ago - Ironwood CMO Michael Shetzline to retire, Jeffrey Silber to succeed - TheFly
- 5 weeks ago - Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients - Business Wire